NCT03816319 2026-03-17
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
Phase 1 Recruiting
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Apollo Therapeutics Ltd
First Affiliated Hospital of Zhejiang University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology